
OSE Immunotherapeutics said both Tedopi combinations met the primary endpoint in a Phase 2 lung cancer trial, with results due at ESMO.
OSE Immunotherapeutics said Tedopi combinations met the primary endpoint in a Phase 2 trial of second-line treatment for metastatic non-small cell lung cancer. One-year overall survival was 47% with Tedopi plus docetaxel and 46% with Tedopi plus nivolumab.
The company said both rates were statistically significant, while the docetaxel-only group had a one-year survival rate of 29%, which was not statistically significant. Bayesian analyses indicated a greater than 90% probability that each combination improved one-year survival versus docetaxel alone.
Treatment-related adverse events occurred in 89% of patients receiving Tedopi plus docetaxel, 82% with Tedopi plus nivolumab and 79% with docetaxel alone. OSE reported no unexpected safety signals.
Lead investigator Federico Cappuzzo is due to present the final results on October 25 at the ESMO annual meeting in Madrid. OSE said its Phase 3 ARTEMIA study of Tedopi alone is recruiting patients, with results expected in early 2028.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.